JPRN-UMIN000001738已完成2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation - Phase II study of gefitinib therapy inserted by chemotherapy for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation
Thoracic Medical Oncology, National Cancer Center Hospital0 个研究点目标入组 33 人开始时间: 2009年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) EGFR mutation that associates with gefitinib resistance (exon 20 T790M) or K-ras mutation 2) CNS metastasis requiring treatment 3) Interstitial pneumonitis or pulmonary fibrosis as determined from chest CT 4) Complications like below a) Active infection b) Acute myocardial infarction, the other severe heart diseases, and arrhythmia within the previous 6months c) Uncontrollable diabetes mellitus d) Uncontrollable hypertension e) Continuous diarrhea and ileus f) Psychological disorders difficult to cooperate in the clinical trial 5) Receiving systemic corticosteroid therapy 6) Active metachronous cancer (disease-free survival of less than 5years) 7) Pregnancy or breast-feeding 8) No intent to practice contraception 9) Difficult to take medicine continuously
研究者
相似试验
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
2 期
Randomized phase II study of continuous gefitinib plus chemotherapy versus alternation of gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations (NEJ005/TCOG0902)on-small cell lung cancer with EGFR mutations (non-squamous histology)JPRN-UMIN000002789orth East Japan Study Group/The Tokyo Cooperative Oncology Group80
已完成
2 期
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21